Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01436305 · ClinicalTrials.gov registry record · Phase 2
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01436305 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 19 participants.
The verdict
NCT01436305, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study was to assess whether a new drug, Nulojix® (belatacept), would minimize serious long term side effects associated with anti-rejection medications while still protecting the new kidney from damage. The researchers also wanted to learn more about the safety of this treatment and long term health of the transplanted kidney.
Interventions
- DRUG Alemtuzumab
- DRUG MMF
- BIOLOGICAL Basiliximab
- DRUG Short-term Tac
- DRUG tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01436305
The ClinicalTrials.gov registry entry for NCT01436305 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Alemtuzumab is the first listed.
NCT01436305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01436305 about?
NCT01436305 is a clinical study titled "Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation". The purpose of this study was to assess whether a new drug, Nulojix® (belatacept), would minimize serious long term side effects associated with anti-rejection medications while still protecting the new kidney from damage. The researchers also wanted to learn more about the safety of this treatment ...
What is the current status of trial NCT01436305?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2011-09. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01436305?
The interventions under investigation include: Alemtuzumab (DRUG), MMF (DRUG), Basiliximab (BIOLOGICAL), Short-term Tac (DRUG), tacrolimus (DRUG).
Who is sponsoring clinical trial NCT01436305?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.